Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2965 Molecular Signature of Rectal Neuroendocrine Neoplasia

Introduction: Rectal neuroendocrine tumors are rare neuroendocrine neoplasias (NEN). Little is known about prevalence and type of somatostatin receptor subtypes (sstr) expression and somatic mutations in relation to long-term clinical outcome.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Unger N, Theurer S, Herold T, Weber F, Dralle H,

Keywords: Somatic Mutations, NGS, Somatostatin receptor subtypes, Intestinal NEN,

#1224 A Randomized Open-label Phase II Study of Everolimus Alone or in Combination with Pasireotide LAR in Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): COOPERATE-2 Trial

Introduction: Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtypes 1-3 and 5. An earlier phase I study showed antitumor activity of everolimus+pasireotide LAR (EVE+PAS) in NET.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Kulke M, Ruszniewski P, Van Cutsem E, Valle J, De Herder W,

Keywords: everolimus, pNET, pasireotide LAR,

#791 Quantification of Somatostatin Receptor Subtypes Using In Vivo PET/CT-Data, Ex Vivo Conventional Immunohistochemistry and Automated Digitized Analysis by Definiens XD Image Software

Introduction: Diagnostics and therapy of NET are significantly influenced by their somatostatin receptor (SSTR) status. Immunohistochemistry (IHC) of SSTR performed by pathologists is a time-consuming and cost-intensive procedure.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Kaemmerer D, Athelogou M, Lupp A, Schulz S, Peter L,

Keywords: SSTR,

#446 Comparative Expression Analysis of Somatostatin Receptor Subtypes in Human Neuroendocrine Tumors Using Two Sets of New Monoclonal Antibodies

Introduction: Expression of somatostatin receptor subtypes (sstr) is required for the successful use of somatostatin analogues (SSA) in the treatment of neuroendocrine tumors (NET). Reliable detection of sstr could improve the selection of SSA treatment. Rabbit and mouse monoclonal antibodies (mAbs) were recently developed independently in Jena and Basel.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Lambertini C, Nuciforo P, Schulz S, Schmid H,

Keywords: sstr, NET, sstr-specific mAb,

#302 Monoclonal Antibodies Against the Human Somatostatin Receptor Subtypes 1-5: Characterization and Immunohistochemical Application in Gastrointestinal Neuroendocrine Tumors

Introduction: A lack of well-characterized somatostatin receptor (sstr)-specific antibodies has hampered development of routine sstr expression profiles that may be useful in the treatment of NET patients (pts).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Lambertini C, Schmid H, Kaufmann M, Nuciforo P,

Keywords: Somatostatin receptor, neuroendocrine tumors, somatostatin receptor-specific monoclonal antibodies,

Abstract Submissions in 2022

Abstract submissions for 2022 will open in September 2021!

 

The 19th Annual ENETS Conference in 2022 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.